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Abstract
Background: Little is known about the clinical features and prognostic factors of bone metastases of
hepatocellular carcinoma (HCC) following liver transplantation (LT).
Methods: All adult patients undergoing LT from 2001 to 2010 were reviewed. Patients with HCC bone metastases
after LT received external beam radiotherapy(EBRT) during this period. Demographic variables, laboratory values,
and tumor characteristics were determined before LT and EBRT. Total radiation dose ranged from 8 to 60 Gy
(median dose 40.0 Gy).
Results: The trunk was the most common site of bone metastases with finding of expansile soft-tissue masses in
23.3% of patients. Overall pain relief from EBRT occurred in 96.7% (29/30). No consistent dose-response relationship
was found for palliation of with doses between 30 and 56 Gy (P = 0.670). The median survivals from the time of
bone metastases was 8.6 months. On univariate and multivariate analyses, better survival was significantly
associated with a better Karnofsky performance status (KPS) and well-controlled intrahepatic tumor, but not with
lower alpha-fetoprotein levels. The median time from LT to bone metastases was 7.1 months. Patients exceeding
the Shanghai criteria presented with bone metastases earlier than those within the Fudan criteria. Patients with
soft-tissue extension always had later bone metastases. The majority of deaths were caused by liver failure due to
hepatic decompensation or tumor progression.
Conclusion: The prognostic factors of bone metastases of HCC following LT are KPS and well-controlled
intrahepatic. Even though survival is shorter for these patients, EBRT provides effective palliation of pain.
Keywords: Transplantation, Hepatocellular carcinoma, Bone metastases, Radiotherapy
Introduction
Over the last 30 years, liver transplantation (LT) was
established as a durable therapy for all forms of end-
stage liver disease [1,2]. Early experience with LT for
management of hepatocellular carcinoma (HCC)
resulted in poor post-transplantation survival and high
recurrence rates that were attributed to suboptimal
patient selection. Currently, preoperative imaging cri-
teria based on the size and number of tumors are used
to select candidates for LT. The Model for End Stage
Liver Disease scoring system introduced in 2002 now
offers priority for patients with HCC within the conven-
tional Milan criteria [3]. These criteria were expanded
by the University of California San Francisco [4] and
Shanghai criteria [5], and those with tumors that exceed
these criteria are at higher risk for recurrence and/or
metastases. Bone is the second most common site of
extrahepatic tumor metastases following the lung [6,7].
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independent predictor of poor outcome in patients with
HCC recurrence following transplantation [6]. However,
the clinical features and prognostic factors in patients
with bone metastases from HCC after LT are rarely
reported [8]. In this study, we retrospectively analyzed
30 patients with bone metastases from HCC after LT in
order to identify prognostic factors and to explore a
effective treatment.
Patients and methods
Eight hundred fifty-three consecutive patients who
underwent LT for the management of HCC between
April 2001 and June 2010 at the Liver Cancer Institute,
Zhongshan Hospital, Fudan Un i v e r s i t yw e r er e v i e w e d .
Patients were identified from the Institute’s prospec-
tively collected database. A total of 30 patients under-
going external bean radiotherapy (EBRT) for bone
metastases were identified among these LT patients.
Ethics approval for the use of human subjects was
obtained from the research ethics committee of Zhong-
shan Hospital, and informed consent was obtained from
each patient.
Diagnosis of HCC was established by a combination of
imaging studies and measurement of alpha-fetoprotein
(AFP) levels prior to LT with final confirmation by
explant pathology, without routine use of pretransplant
tumor biopsy. Disease extent was determined by preo-
perative computed tomography (CT) or magnetic reso-
nance imaging (MRI) performed within 3 months before
L T .T h et w om o d a l i t i e ss h o wed consistent results.
Extrahepatic metastasis was excluded based on chest
and abdominal CT or MRI, and bone scintigraphy per-
formed within 1 month before LT. Patients underwent
classic orthotopic LT. Immunosuppressive therapy after
LT consisted of a triple drug regimen of cyclosporine or
tacrolimus combined with corticosteroids and/or myco-
phenolate mofetil [5]. Patients with HCC were classified
as having tumors either meeting the Milan criteria [9],
beyond Milan criteria but within the University of Cali-
fornia San Francisco criteria [10], or within the Shanghai
criteria. For Shanghai criteria, we determined that
expansion of Milan criteria to include: a solitary lesion
≤9 cm in diameter, no more than three lesions with the
largest ≤5 cm, a total tumor diameter ≤9c mw i t h o u t
macrovascular invasion, lymph node invasion and extra-
hepatic metastasis [5].
Diagnosis of bone metastases was based on the history
of HCC, presence of symptoms, and radiologic imaging
studies. The confirmation of bone metastases by histolo-
gic testing was not recommended in this study. All
patients were required to undergo technetium-99 m
bone scintigraphy, which is the best method for screen-
ing patients at risk for bone metastasis and is useful for
evaluating the extent of metastatic bone disease. Bone
scintigraphy is not specific for metastatic disease, and
positive findings must often be confirmed using other
imaging studies [11]. A confirmatory study (MRI, as a
first choice, or CT) was especially important in deter-
mining the presence of soft-tissue extension, bone
destruction, or spinal cord compression, and the extent
of osteolytic or osteoblastic metastases [12]. Pure osteo-
lytic metastasis was defined as bone destruction without
new bone formation, as determined by CT scan or MRI,
and no increased isotope uptake ("hot” spot) detected at
the corresponding area on bone scan. Osteoblastic
metastasis was defined as new bone formation visible by
CT scan or MRI in the involved bone, with increased
isotope uptake detected at the corresponding area on
bone scan. Mixed osteolytic and osteoblastic lesions
were the most common in patients with bone metas-
tases from HCC [12]. The imaging diagnosis of bone
metastasis was based on the combination with bone
scintigraphy and computed tomography in 14 patients
or magnetic resonance imaging in 16 patients. Positron
emission tomography scanning to evaluate areas of
increased metabolic activity was not routinely used in
this study.
Indications for EBRT for bone metastases included
pain, risk for pathologic fracture, and neurological com-
plications arising from spinal cord compression and
nerve root pain. Patients with multiple bone metastases,
whose lesions caused pain or possibly spinal cord com-
pression, were first considered for EBRT. Bone metas-
tases status was recorded at the initial radiotherapy
session. Radiation was delivered through a single poster-
ior field or parallel opposed fields, depending on the
location and depth of lesions base on CT or MRI. Most
therapy was provided with 6- or 15-MV photons; how-
ever, electron therapy was also selected for those with
shallow lesions such as in the ribs, skull, or extremities.
Radiation fields included gross tumor volume and 1- to
1.5-cm margins. In the case of vertebral bone metas-
tases, radiation fields usually encompassed one normal
vertebra above and below the metastatic lesions. If the
lesions presented with concurrent soft-tissue extension,
the radiation fields were enlarged on the basis of CT or
MRI results. We scheduled the full radiation dosage at
46 Gy for the vertebral metastatic lesions and 50-60 Gy
for soft-tissue involvement beyond the spinal cord, in
daily doses of 2 Gy/fraction five times a week. Factors
that necessitated a reduced dose were progressive pri-
mary disease, many lesions, poor performance status,
adverse effects, and patient inconvenience during EBRT.
Well-controlled intrahepatic primary tumors were
defined as follows: (1) after liver transplantation, follow-
up enhanced CT or MRI (or both) did not show any
new lesions during the periods of EBRT, and (2) after
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radiofrequency ablation, lipiodol was deposited in the
entire intrahepatic tumor, or destruction of tumor
within the zone of ablation, the follow-up enhanced CT
or MRI did not show any new lesions, including the
edge of primary tumors, during the periods of EBRT.
Otherwise, the patients were regarded as having uncon-
trolled primary lesions.
In this study, we assigned Dr. Jian He who is the first
author in this paper to focus on this study for 10 years
(from 2001 to 2010). He recorded the patients’ clinical
data and followed up every patient. The pain measure-
ments were done pre- and post RT using a visual analo-
gue scale, which is part of routine practice at our
institution [12].
Pretreatment evaluation included a medical history
and physical examination, complete blood cell count,
serum chemistries, liver function tests, AFP for those
who tested positive at the initial evaluation, chest X-ray,
abdominal ultrasonography, bone scintigraphy, and
enhanced CT or MRI (or both). Clinical monitoring was
performed once a week. Liver function was estimated
using the Child-Pugh classification, which was scored
based on the levels of serum bilirubin, serum albumin,
prothrombin time prolongation, presence or absence of
ascites, and encephalopathy.
Two survival intervals were estimated in this study.
One was survival after bone metastases, i.e., the interval
from the date when bone metastases were confirmed to
death or the last follow-up. The other was bone metas-
tasis-free survival, which was defined as the time from
the date of LT to the date bone metastases were con-
firmed. Cumulative survival rates were analyzed using
Kaplan-Meier curves. The median follow-up from EBRT
is 9.7 (range: 0.83-63.87) months.
The trend c
2 test was used to compare dose-response
results. The Pearson c
2 test or Fisher’s exact probability
was calculated to measure correlation among the vari-
ables. Potential prognostic factors were evaluated with
respect to survival. For multivariate analysis, all variables
were entered using the Backward-Wald method. Logistic
regression was used to predict a categorical variable
from a set of predictor variables in bone metastasis-free
survival after LT. A P ≤ 0.05 was considered statistically
significant. All calculations were performed using SPSS
13.0 for Windows (SPSS, Chicago, IL).
Results
Clinical features
The cohort included 26 men and 4 women (ratio 6.5:1),
with a mean age of 49.6 ± 10.0 years (range, 30-69
years). EBRT was performed on a total of 49 metastatic
sites. The trunk was the most common site of bone
metastases, with metastases most frequently occurring
in the thorax (43.4%), pelvis (24.5%), and lumbar spine
(9.4%), as shown in Table 1. All 30 patients in this
cohort had a combination of both osteolytic and osteo-
blastic components. No patient appeared to have purely
osteolytic lesions, for which false-negative readings were
presented in the bone scintigraphy. Bone metastases
with expansile soft-tissue masses were found in seven
patients (23.3%).
Response
Of 30 patients with bone metastases from HCC after
LT, complete pain relief (CR) with EBRT occurred in
nine (30.0%) patients and partial pain relief (PR) in 20
(66.7%). There was no response to EBRT in one patient
who received 8 Gy/4 Fx radiation. The association
between radiation dose and response was not significant
(X
2 = 0.800, P = 0.670) in patients with CR and PR. It
appears there is no consistent dose-response relation for
the palliation of bone metastases (Table 2).
Table 1 Sites of bone metastases in 30 HCC patients after
liver transplantation
Bone sites Present sites Radiation sites
Skull 3 (5.7%) 3 (6.1%)
Cervical vertebrae 3 (5.7%) 2 (4.1%)
Upper limb
Humerus 1 (1.9%) 0 (0%)
Thorax
Thoracic vertebrae 8 (15.1%) 8 (16.3%)
Rib 12 (22.6%) 11 (22.4%)
Sternum 3 (5.7%) 3 (6.1%)
Lumbar vertebrae 5 (9.4%) 5 (10.2%)
Pelvis
Sacrum 2 (3.8%) 1 (2.0%)
Sacroiliac joint 2 (3.8%) 2 (4.1%)
Ilium 4 (7.4%) 4 (8.2%)
Ischium 1 (1.9%) 1 (2.0%)
Acetabulum 4 (7.4%) 4 (8.2%)
Lower limb
Femur 5 (9.4%) 5 (10.2%)
Total 53 49
Table 2 Dose and response
Total dose CR PR Total P value
30 to < 40 Gy 1 (25.0%) 3 (75.0%) 4 0.670
≥40 to 46 Gy 6 (28.6%) 15 (71.4%) 21
≥50 to 60 Gy 2 (50.0%) 2 (50.0%) 4
Total 9 20 29
Pearson’s chi-square is used to assess P value
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The 1-year, 2-year, 3-year, and median survivals from the
time of LT were 70.0%, 38.6%, 31.6%, and 18.0 months,
respectively. The 1-year, 2-year, and median survivals
from the time of bone metastases were 39.7%, 24.4%, and
8.6 months, respectively. The impact of potential prognos-
tic factors on survival is shown in Table 3. On univariate
and multivariate analyses, better survival was significantly
associated with a better Karnofsky performance status and
well-controlled intrahepatic tumor as shown in Figure 1.
Table 3 Univariate and multivariate analysis of predictors of survival after bone metastases in 30 HCC patients
undergoing LT
No. Survival status P value
1-year 2-year Median Univariate Multivariate
Pre-LT
Gender Female 4 50.0 0 2.7 0.241 0.428
Male 26 42.3 29.0 8.6
Age (years) ≤50 17 28.2 21.2 8.6 0.697 0.180
>50 13 46.2 19.2 15.1
HbsAg - 3 0 0 5.0 0.190 0.201
+ 27 44.1 27.1 9.8
Γ-GT ≤75 14 42.9 21.4 11.2 0.814 0.099
>75 16 30.0 20.0 6.3
AFP ≤400 16 37.5 23.4 8.6 0.738 0.557
>400 14 34.3 17.1 6.3
Child-Pugh Classification A 22 26.5 21.2 6.3 0.240 0.099
B 8 62.5 33.3 16.6
Shanghai criteria Exceeding 14 34.3 12.9 8.6 0.962 0.570
Within 16 37.5 18.8 7.9
UCSF Exceeding 18 38.1 8.5 8.6 0.597 0.972
Within 12 33.3 33.3 6.3
Milan Exceeding 20 50 20 11.2 0.939 0.364
Within 10 20 20 4.1
Interval between diagnosis of HCC and LT ≤0.5 year 17 35.3 22.1 8.6 0.947 0.976
>0.5 year 13 36.9 18.5 9.8
Post-LT
KPS ≥80 14 56.3 30.1 15.6 0.032 0.003
<80 16 18.8 12.5 4.1
Γ-GT ≤75 11 53.0 31.8 23.9 0.116 0.385
>75 19 26.3 14.0 6.3
AFP ≤400 15 40.0 25.0 11.2 0.531 0.926
>400 15 32.0 16.0 5.0
Child-Pugh Classification A 23 43.0 27.3 11.2 0.209 0.294
B 7 14.3 0 6.3
Soft-tissue extension Absent 23 29.8 19.9 7.9 0.470 0.974
Present 7 57.1 19.0 23.9
No. of bone metastases Solitary 14 50.0 25.7 15.6 0.245 0.456
≥2 sites 16 23.4 15.6 7.9
Intrahepatic tumor control uncontrolled 10 20.0 10.0 3.0 0.003 0.008
Well-controlled 20 55.0 31.4 15.1
Concurrent metastases Absent 15 38.9 15.6 4.1 0.565 0.170
Present 15 40.0 24.0 9.8
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The median time from LT to bone metastases was 7.1
months (mean time 14.5 months with range between 0.5
and 45.6 months). Patients who exceeded the Shanghai
criteria presented with bone metastases earlier than those
within Shanghai criteria (Logistic P = 0.053, Figure 2a).
Patients with earlier bone metastases had higher incidence
of intrahepatic uncontrolled tumor (Logistic P =0 . 0 1 8 ,
Figure 1 Survival curves are shown based on a Karnofsky performance status and b intrahepatic tumor status.
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metastases. Patients with soft-tissue extension always had
later bone metastases as shown in Figure 2c and Table 4.
Failure patterns and toxicity
At the end of this study, five patients (16.7%) were alive
and 25 (83.3%) had died. The causes of death were liver
Figure 2 The probability of bone metastases with the time to bone metastases after LT for different tumor status.
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sion, or both in 21 patients (84.0%); brain metastases in
2 patients (8.0%); lung infection in 1 patient (4.0%); and
stroke in 1 patient (4.0%).
Acute radiation toxicity was mild or absent in all
patients. If the radiation field involved the gastrointest-
inal area (such as bone metastases located between thor-
acic vertebra 10 and the sacrum), patients had mild loss
of appetite and occasional nausea. Localized hair loss
was found in patients with irradiation to the skull. Loca-
lized pigmentation change was found in the radiation
fields. None of these adverse effects affected the timing
or delivery of EBRT. No medical management was
required for any radiation-associated toxicity.
Discussion
A few articles have reported the natural history, effects of
medical or surgical treatment, and predictors of survival
in patients who develop recurrence of HCC after LT.
There are no systematic reports on bone metastases from
HCC after LT. Dr. Roayaie et al. previously reported a
median survival of 5-6 months in 19 patients, which was
the largest cohort of patients studied with bone metas-
tases after LT [6]. Irrespective of other sites of metastasis,
t h ep r e s e n c eo fb o n em e t a s t a s e sw a ss h o w nt ob ea n
independent predictor of poor outcome in patients with
post-transplant HCC recurrence [6]. Treatments for
bone metastases are aimed at palliating symptoms, and
have the same modest role in the post-transplant setting
as in non-transplant patients. Local radiotherapy provides
effective palliation of painful skeletal lesions [12,13]. Sur-
vival and pain response rates are similar to those in
patients without LT as we reported previously [12].
The clinical features of bone metastases from HCC
a f t e rL Tm i m i co t h e rm a l i g n a ncies including those in
HCC without LT, in which bone metastases most
Table 4 Bone metastases free survival after LT
Bone metasta ses-free survival P value
≤ 1 year > 1 year c
2 test Logistic
Gender Female 2 (6.7%) 2 (6.7%) 1.00
Male 16 (53.3%) 10 (33.3%)
Age ≤50 11 (36.7%) 6 (20.0%) 0.711
>50 7 (23.3%) 6 (20.0%)
HbsAg - 3 (10.0%) 0 (0%) 0.255
+ 15 (50.0%) 12 (40.0%)
Γ-GT ≤75 8 (26.7%) 6 (20.0%) 1.00
>75 10 (33.3%) 6 (20.0%)
AFP ≤400 9 (30.0%) 7 (23.3%) 0.722
>400 9 (30.0%) 5 (16.7%)
Child-Pugh Classification A 14 (46.7%) 8 (26.7%) 0.678
B 4 (13.3%) 4 (13.3%)
Shanghai criteria Exceeding 11 (36.7%) 3 (10.0%) 0.072 0.053
Within 7 (23.3%) 9 (30.0%)
UCSF Exceeding 13 (43.3%) 5 (16.7%) 0.136
Within 5 (16.7%) 7 (23.3%)
Milan Exceeding 13 (43.3%) 7 (23.3%) 0.694
Within 5 (16.7%) 5 (16.7%)
Interval between diagnosis of HCC and LT ≤0.5 year 8 (26.7%) 9 (30.0%) 0.141
>0.5 year 10 (33.3%) 3 (10.0%)
Soft-tissue extension Absent 16 (53.3%) 5 (16.7%) 0.013 0.052
Present 2 (6.7%) 7 (23.3%)
No. of bone metastases Solitary 6 (20.0%) 8 (26.7%) 0.135
≥2 sites 12 (40.0%) 4 (13.3%)
Intrahepatic tumor control uncontrolled 9 (30.0%) 1 (3.3%) 0.045 0.018
Well-controlled 9 (30.0%) 11 (36.7%)
Concurrent distant metastases Absent 10 (33.3%) 5 (16.7%) 0.710
Present 8 (26.7%) 7 (23.3%)
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sites of bone metastases are the spine and ribs. How-
ever, bone metastases from HCC have their own charac-
teristics. It is interesting to note that while nearly 40%
of patients without LT had an accompanying hypervas-
cular soft-tissue mass [12], only 23.3% of patients in this
study showed accompanying hypervascular soft-tissue
lesions. We do not know the factors contributing to the
presence of expansile soft-tissue masses, but they are
associated with the recurrence time between LT and
bone metastases. Patients with soft-tissue extension
always had delayed bone metastases (≥ 6 months).
Even though the treatment for bone metastases is the
same in patients with and without LT, there are slight
differences in both clinical features and prognosis.
Poorer survival was found to be significantly associated
with a higher AFP level in patients without LT [12];
however, the difference was not significant in patients
with LT in this study. AFP is a serum marker that is ele-
vated in 50-80% of patients with HCC. AFP is a signifi-
cant independent predictor of survival as reported by
many authors. Patients with normal AFP levels survive
longer than those with elevated levels [14-16]. AFP can
induce functional impairments in dendritic cells [17],
resulting in these cells displaying an immature pheno-
type and/or defective functi o ni np e r i p h e r a lb l o o do f
patients with HCC [18]. Priming of immune responses
against AFP results in significant protective antitumoral
T-cell responses in a mouse model [19]. All patients
including AFP positive and negative patients are treated
with immunosuppressive drugs to prevent rejection after
LT. This may be useful for explaining the difference
between the patients with and without LT.
There was a wide time range from LT to recurrence
and in post-recurrence survival. In a series of 311
patients who underwent LT for HCC at Mount Sinai
Medical Center, 57 patients had a median recurrence
time of 12.3 months following transplantation [6]. Simi-
lar results were reported from Korea [20] and Spain
[21]. In this study, the median time from LT to bone
metastases was 7.1 months, which is shorter than in
those with distant metastases beyond bone. Dr. Shin et
al. reported that the median survival time after recur-
rence was 11.7 months, and the 1- and 3-year survival
rates after recurrence were 52.8% and 15.8%, respec-
tively [20]. After recurrence, the median survival was 7
months in 28 patients [7] and 8.7 months in 57 patients
[6]. Our results showed that median survival after bone
metastases is 8.6 months, which is between the times
reported by the studies mentioned above. The prognosis
of bone metastases after LT may be similar to those
patients with metastases to other sites.
Limitations to our study are small patient numbers, a
wide range of radiation doses (8-60 Gy), and lack of the
incidence rate for bone metastases. Bone metastases
from HCC itself rarely cause patient death, but bone
metastases are a common cause of pain and other sig-
nificant symptoms that are detrimental to quality of life.
The differences in radiation dose did not affect survival.
Patients with bone metastases were referred from sur-
geons to our department; and we did not know the
exact number of patients with bone metastases who did
not have symptoms. HCC recurrence after LT can be
minimized or prevented by employing strict selection
criteria. The incorporation of molecular data into clini-
cal practice has the potential both to prevent recurrence
through improved case selection [22], and to guide
treatment by identifying patterns of gene expression that
predict response to targeted therapies.
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